市場調查報告書
商品編碼
1419650
誘導多能幹細胞生產市場 - 按製程(手動、自動化)、產品和服務(消耗品和套件、儀器、服務)、應用(藥物開發和發現、再生醫學)、最終用途和全球預測,2024-2032 年Induced Pluripotent Stem Cells Production Market - By Process (Manual, Automated), Product & Service (Consumables & Kits, Instruments, Service), Application (Drug Development & Discovery, Regenerative Medicine), End-use, & Global Forecast, 2024-2032 |
由於再生醫學研究和開發計畫的不斷升級,2023 年至 2032 年間,全球誘導多能幹細胞生產市場將以 9.8% 的複合CAGR成長。研究機構和生物製藥公司之間的合作正在加強,促進技術進步,並加速基於 iPSC 的治療應用。隨著學術界和工業界之間協同作用的加強,在利用 iPSC 潛力提供個人化醫療和再生療法創新解決方案的共同努力的推動下,市場將大幅成長。
例如,2023 年,SCG Therapy 在新加坡開設了最先進的細胞療法製造廠和研發中心。該工廠利用先進的細胞治療製造和現成的人類誘導多能幹細胞(iPSC)技術,旨在向亞太地區、歐洲和北美的合作醫院提供細胞治療產品,增強SCG在全球市場的能力。此舉標誌著 SCG 對加強誘導多能幹細胞生產產業、增強生產能力以滿足全球需求和滿足日益成長的患者需求做出了重大貢獻。
誘導多能幹細胞生產市場根據最終用途、應用和地區而分散。
在對 iPSC 創新研究和治療應用的日益關注的推動下,研究和學術機構部門將在 2032 年建立重要的市場立足點。研究機構利用 iPSC 技術進行疾病建模、藥物發現和再生醫學研究,為市場的成長做出了重大貢獻。隨著幹細胞研究合作和資金的激增,研究和學術機構部門將成為 iPSC 生產市場的關鍵驅動力。
由於 iPSC 在治療各種疾病的再生療法中的應用不斷增加,到 2032 年,再生醫學領域將大幅成長。隨著再生醫學因其在組織修復和器官再生方面的潛力而受到關注,iPSC 在推動這些創新治療方法方面發揮關鍵作用。再生醫學產業越來越關注基於 iPSC 的解決方案,這將使其成為市場擴張的關鍵貢獻者。
由於歐洲對生物醫學研究的強勁投資、有利的監管框架以及對再生醫學的日益重視,歐洲誘導多能幹細胞生產產業將在 2023 年和 2032 年實現顯著的CAGR。歐洲國家對推動 iPSC 技術的臨床應用做出了重大承諾,推動市場成長。憑藉蓬勃發展的生物技術格局和戰略合作,歐洲將成為影響 iPSC 生產佔有率的關鍵貢獻者。
Global Induced Pluripotent Stem Cells Production Market will grow at a 9.8% CAGR between 2023 and 2032, owing to the escalating research and development initiatives in regenerative medicine. Collaborations between research institutions and biopharmaceutical companies are intensifying, fostering technological advancements, and accelerating iPSC-based therapeutic applications. As the synergy between academia and industry strengthens, the market will witness substantial growth, propelled by the combined efforts to harness the potential of iPSCs for innovative solutions in personalized medicine and regenerative therapies.
For instance, in 2023, SCG Therapy inaugurated a state-of-the-art cell therapy manufacturing facility and R&D center in Singapore. Leveraging advanced cell therapy manufacturing and off-the-shelf human-induced pluripotent stem cell (iPSC) technology, the facility aims to supply cell therapy products to partner hospitals across Asia Pacific, Europe, and North America, enhancing SCG's capabilities in the global market. This move marks SCG's significant contribution to strengthening the induced pluripotent stem cells production industry, augmenting production capabilities to meet global demand and address increasing patient needs.
The induced pluripotent stem cells production market is fragmented based on end-use, application, and region.
The research and academic institutes segment will establish a significant market foothold by 2032, fueled by the increasing focus on iPSCs for innovative research and therapeutic applications. Research institutions leverage iPSC technology for disease modeling, drug discovery, and regenerative medicine studies, significantly contributing to the market's growth. With a surge in collaborations and funding for stem cell research, the research and academic institutes segment will stand as a key driver in the iPSC production market.
The regenerative medicine segment will witness a substantial upswing by 2032, attributed to the growing application of iPSCs in regenerative therapies for treating various medical conditions. As regenerative medicine gains traction for its potential in tissue repair and organ regeneration, iPSCs play a pivotal role in advancing these innovative therapeutic approaches. The regenerative medicine sector's increasing focus on iPSC-based solutions will position it as a key contributor to market expansion.
Europe induced pluripotent stem cells production industry will register a notable CAGR during 2023 and 2032 due to its robust investments in biomedical research, favorable regulatory frameworks, and an increasing emphasis on regenerative medicine. European countries exhibit a significant commitment to advancing iPSC technology for clinical applications, driving market growth. With a thriving biotechnology landscape and strategic collaborations, Europe will stand as a key contributor to shaping the share of iPSC production.